Pfizer Plans To Present Latest Results From Its Genitourinary Portfolio At ASCO GU Cancers Symposium Taking Place February 13-15 In San Francisco, California

Pfizer Inc.

Pfizer Inc.

PFE

0.00
  • More than 20 abstracts span Pfizer's leading genitourinary cancer portfolio of approved standards of care and growing pipeline across prostate and bladder cancers
  • Detailed overall survival (OS) results from the pivotal Phase 3 TALAPRO-2 trial of TALZENNA® in combination with XTANDI® in patients with metastatic castration-resistant prostate cancer (mCRPC)
  • Updated analysis from the Phase 3 EV-302 trial highlights sustained OS benefit of PADCEV® in combination with pembrolizumab in locally advanced or metastatic urothelial cancer
  • First randomized progression-free survival (PFS) data for mevrometostat in combination with XTANDI in mCRPC
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.